Rapt Therapeutics Stock Fundamentals
| RAPT Stock | USD 1.14 0.03 2.56% |
RAPT Therapeutics fundamentals help investors to digest information that contributes to RAPT Therapeutics' financial success or failures. It also enables traders to predict the movement of RAPT Stock. The fundamental analysis module provides a way to measure RAPT Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to RAPT Therapeutics stock.
RAPT |
RAPT Therapeutics Company Return On Equity Analysis
RAPT Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current RAPT Therapeutics Return On Equity | -0.77 |
Most of RAPT Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, RAPT Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, RAPT Therapeutics has a Return On Equity of -0.7709. This is 96.78% lower than that of the Biotechnology sector and 97.89% lower than that of the Health Care industry. The return on equity for all United States stocks is 148.68% higher than that of the company.
RAPT Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining RAPT Therapeutics's current stock value. Our valuation model uses many indicators to compare RAPT Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across RAPT Therapeutics competition to find correlations between indicators driving RAPT Therapeutics's intrinsic value. More Info.RAPT Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value RAPT Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.RAPT Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RAPT Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of RAPT Therapeutics could also be used in its relative valuation, which is a method of valuing RAPT Therapeutics by comparing valuation metrics of similar companies.RAPT Therapeutics is currently under evaluation in return on equity category among its peers.
RAPT Fundamentals
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | (72.12 M) | ||||
| Shares Outstanding | 132.01 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 96.42 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Book | 0.81 X | ||||
| Price To Sales | 411.22 X | ||||
| Gross Profit | 1.53 M | ||||
| EBITDA | (136.1 M) | ||||
| Net Income | (129.87 M) | ||||
| Cash And Equivalents | 207.34 M | ||||
| Cash Per Share | 6.99 X | ||||
| Total Debt | 4.49 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 15.97 X | ||||
| Book Value Per Share | 1.44 X | ||||
| Cash Flow From Operations | (83.3 M) | ||||
| Short Ratio | 4.67 X | ||||
| Earnings Per Share | (3.19) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 68 | ||||
| Beta | -0.31 | ||||
| Market Capitalization | 154.45 M | ||||
| Total Asset | 240.32 M | ||||
| Retained Earnings | (614.55 M) | ||||
| Working Capital | 186.88 M | ||||
| Current Asset | 17 K | ||||
| Current Liabilities | 167 K | ||||
| Net Asset | 240.32 M |
About RAPT Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze RAPT Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RAPT Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RAPT Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Rapt Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 88 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.